A PHASE 3, MULTICENTER, PARALLEL-GROUP, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS ≥50 YEARS OF AGE
Status: Completed
Location: See all (26) locations...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
This purpose of this phase 3 multicenter, parallel-group, open-label study is to learn about the safety, tolerability, and immunogenicity of RSVpreF and HZ/su vaccine when given together in adults 50 years of age and older.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Healthy Volunteers: t
View:
• • Male and female participants 50 years of age and older who are healthy or with stable chronic medical conditions
Locations
United States
Alabama
Central Research Associates
Birmingham
Medical Affiliated Research Center
Huntsville
AMR Clinical
Mobile
California
Kaiser Permanente
Los Angeles
Diablo Clinical Research, Inc.
Walnut Creek
Florida
Alliance for Multispecialty Research, LLC
Doral
Proactive Clinical Research,LLC
Fort Lauderdale
De La Cruz Research Center, LLC
Miami
Georgia
Centricity Research Columbus Georgia Multispecialty
Columbus
Clinical Research Atlanta
Stockbridge
Illinois
Synexus Clinical Research US, Inc.
Chicago
Optimal Research
Peoria
Louisiana
DelRicht Research
New Orleans
Maryland
Jadestone Clinical Research
Silver Spring
Michigan
Oakland Medical Research
Troy
Missouri
Clinical Research Professionals
Chesterfield
New Jersey
IMA Clinical Research Warren
Warren Township
New York
NYU Langone Health
New York
Ohio
Centricity Research Columbus Ohio Multispecialty
Columbus
Pennsylvania
DM Clinical Research - Philadelphia
Philadelphia
Tennessee
Clinical Neuroscience Solutions Inc.
Memphis
Texas
DM Clinical Research - Bellaire
Houston
SMS Clinical Research
Mesquite
IMA Clinical Research San Antonio
San Antonio
DM Clinical Research - Sugar Land
Sugar Land
Other Locations
Puerto Rico
Clinical Research Puerto Rico
San Juan
Time Frame
Start Date: 2025-04-04
Completion Date: 2025-09-30
Participants
Target number of participants: 526
Treatments
Other: Coadministration Group
* Visit 1 (Day 1): RSVpreF + HZ/su dose 1~* Visit 3 (Month 2): HZ/su dose 2
Other: Sequential Administration Group
* Visit 1 (Day 1): HZ/su dose 1~* Visit 2 (Month 1): RSVpreF~* Visit 3 (Month 2): HZ/su dose 2
Related Therapeutic Areas
Sponsors
Leads: Pfizer